X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.
Lead Product(s): mRNA Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Gemcovac-19
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.
Lead Product(s): Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Gemcovac-Om
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.
Lead Product(s): mRNA Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Gemcovac-19
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Gemcovac-19, the first mRNA Covid-19 vaccine developed in India, and only third mRNA vaccine to be approved for COVID-19 in the world, received the Emergency Use Authorization (EUA) from DCGI.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: GEMCOVAC-19
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
HGCO19 (mRNA-based Vaccine) has already demonstrated safety, immunogenicity, neutralization antibody activity in rodent models, neutralizing antibody response of vaccine in mice and non-human primates was comparable with sera from convalescent patients of COVID-19.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
HGCO19 (mRNA-based Vaccine) has already demonstrated safety, immunogenicity, neutralization antibody activity in rodent and non-human primate models, neutralizing antibody response of vaccine in mice and non-human primates was comparable with sera from patients of COVID-19.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Company has conducted phase-2/3 trials of vaccine candidates to evaluate its safety, immunogenicity and tolerability on 4,000 participants, for first indigenously developed HGCO19, mRNA vaccine for Covid-19.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2022
Details:
Gennova's synthetic, self-replicating India's first homegrown mRNA vaccine is in Phase III Clinical Trials for the treatment of COVID-19 is currently under final clinical trial stages. .
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2022
Details:
Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.
Lead Product(s): HGCO19
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: HDT Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
HDT Bio has also developed HGCO19, a LION-based COVID-19 vaccine, in collaboration with Gennova Biopharmaceuticals of Pune, which is currently is being tested in India in a Phase 1/2 clinical trial.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: HDT Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
